Adults 18 to 75, any sex, with Back Pain, Low. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Changes in Brain Positron Emission Tomography SignalPrimary· 4 weeks
The investigators will test for the presence of a significant treatment effect in the brain \[11C\]PBR28 signal.
Group
Value
95% CI
CBD Arm
0.00197
± 0.017756865
Changes in Pain Outcomes as Measured by Self Report on a 0-10 Numerical Pain Rating Scale (Worst Pain in the Past 24 Hours).Secondary· 4 weeks
The investigators will test for the presence of a significant treatment effect in pain outcomes on a self reported numerical (0-10) pain rating scale. Higher number indicates worse pain.
Group
Value
95% CI
CBD Arm
4.5
± 0.707106781
Adverse events — posted to ClinicalTrials.gov
Time frame: From enrollment to 2 weeks following study medication discontinuation (6 weeks).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation. The efficacy of CBD use for low back pain treatment will also be evaluated by observing whether CBD administration will reduce neuroinflammation and low back pain symptoms.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use
· Phase 2, PHASE3
· not yet recruiting
NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress
· Phase 1, PHASE2
· recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
· Phase 2
· recruiting
NCT06381180 — Warrior CARE: Cannabis Behavioral Health
· Phase 1, PHASE2
· not yet recruiting
NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
· Phase 1
· completed
Other recruiting trials for Back Pain, Low
Currently open trials in the same condition.
NCT06825390 — AuriculoTherapy NeuroImaging
· NA
· recruiting
NCT06345690 — VIA Disc NP Registry 3.0
· recruiting
NCT04287413 — Determining the Impact of a New Physiotherapist-led Primary Care Model for Low Back Pain
· NA
· active not recruiting
NCT05821530 — HFIT Versus TENS Study for Chronic Low Back and Knee Pain
· NA
· active not recruiting
NCT06410794 — Virtual Reality Training in Occupational Rehabilitation
· NA
· active not recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
· withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg
· NA
· not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior
· NA
· not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries
· NA
· not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03891264.